This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Shire PLC (SHP.L) - Shire has agreed to buy NPS Pharmaceuticals Inc for $5.2bn in its biggest acquisition yet, as the Dublin-based drugmaker strengthens its position in the lucrative field of medicines for rare diseases. Closing Price 4735.00p (Reuters)
Taylor Wimpey (TW.L) - Said prospects for the British market in 2015 were "healthy". It started the year with a record order book of £1.4Bn, up 12% on a year ago. It had completed 12,454 homes in 2014, up 6% on 2013, with an average selling price up 11% to 234,000 pounds ($354,931). Closing price 125.70 (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Dow Jones | DJI.L | -0.95% | 0.04% | -1.24% |
| UK 100 | UKX.L | -1.05% | 0.00% | -1.50% |
| Germany 30 | DAX.L | -1.92% | 0.23% | -2.40% |
| Taylor Wimpey | TW.L | -5.35% | -3.24% | -6.40% |
| Barratt Developments | BDEV.L | -4.88% | -2.03% | -6.07% |
| Tesco | TSCO.L | -2.46% | -0.08% | -3.27% |
| Ted Baker | TED.L | 3.57% | 4.04% | 1.09% |
| Howden Joinery Group Plc | HWDN.L | -0.36% | 0.17% | -2.03% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research